MGNX Stock Price History and Quote Analysis Insights for Investors
MacroGenics, Inc.
Stock Price Today
MacroGenics, Inc. (MGNX) stock declined over -2.87%, trading at $3.39 on NASDAQ, down from the previous close of $3.49. The stock opened at $3.47, fluctuating between $3.38 and $3.53 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Company Information
| Employees | 339 |
| Beta | 2.08 |
| Sales or Revenue | $58.75M |
| 5Y Sales Change% | -0.354% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
MacroGenics, Inc. (NASDAQ: MGNX) stock price is $3.39 in the last trading session. During the trading session, MGNX stock reached the peak price of $3.53 while $3.38 was the lowest point it dropped to. The percentage change in MGNX stock occurred in the recent session was -2.87% while the dollar amount for the price change in MGNX stock was -$0.10.
The NASDAQ listed MGNX is part of Biotechnology industry that operates in the broader Healthcare sector. MacroGenics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Ezio Bonvini
Senior Vice President of Research & Chief Scientific Officer
Mr. James Karrels
Senior Vice President, Chief Financial Officer & Corporation Sec.
Dr. Scott Koenig M.D., Ph.D.
Pres, Chief Executive Officer & Director
Dr. Stephen L. Eck M.D., Ph.D.
Senior Vice President of Clinical Devel. & Chief Medical Officer
Dr. Thomas M. Spitznagel Ph.D.
Senior Vice President of Technical Operations
Mr. Jeffrey Stuart Peters
Senior Vice President, Gen. Counsel & Corporation Compliance Officer
Mr. Eric Blasius Risser
Chief Operating Officer
Ms. Lynn Cilinski
Vice President, Controller & Treasurer
Dr. Christopher Shayne James M.D.
Vice President of Investor Relations
MGNX's closing price is 14.88% higher than its 52-week low of $2.95 where as its distance from 52-week high of $21.88 is -84.51%.
Number of MGNX employees currently stands at 339.
Official Website of MGNX is: https://www.macrogenics.com
MGNX could be contacted at phone 301 251 5172 and can also be accessed through its website. MGNX operates from 9704 Medical Center Drive, Rockville, MD 20850, United States.
MGNX stock volume for the day was 476.96K shares. The average number of MGNX shares traded daily for last 3 months was 640.16K.
The market value of MGNX currently stands at $212.77M with its latest stock price at $3.39 and 62.76M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com